Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 853-862

  Ko, Jae Wook ^a   Sukhova, Nadia ^b   Thacker, David ^b   Chen, Patricia ^b   Flockhart, David A ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; DEXTRORPHAN; ISOENZYME; LANSOPRAZOLE; OMEPRAZOLE; TOLBUTAMIDE;

ARTICLE; COMPETITIVE INHIBITION; DRUG DEGRADATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; CHLORZOXAZONE; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MEPHENYTOIN; MICROSOMES, LIVER; OMEPRAZOLE; PHENACETIN; TOLBUTAMIDE;

EID: 0030811096     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. C. M. Spencer and D. Faulds: Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 48, 404-430 (1994).
2. C. W. Howden: Clinical pharmacology of omeprazole. Clin. Pharmacokinet. 20, 38-49 (1991).
3. T. Andersson, C.-G. Regårdh, M.-L. Dahl-Puustinen, and L. Bertilsson: Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monitor. 12, 415-416 (1990).
4. J. D. Balian, N. Sukhova, J. W. Harris, J. Hewett, L. Pickle, J. A. Goldstein, R. L. Woosley, and D. A. Flockhart: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther. 57, 662-669 (1995).
5. D.-R. Sohn, J.-T. Kwon, and H.-K. Kim: Influence of S-mephenytoin phenotype on lansoprazole metabolism. Clin. Pharmacol. Ther. 59, 137 (abstr.) (1996).
6. J. S. Marinac, J. D. Balian, J. W. Foxworth, S. K. Willsie, J. C. Daus, R. Owen, and D. A. Flockhart: Determination of CYP2C19 phenotype in black americans with omeprazole: correlation with genotype. Clin. Pharmacol. Ther. 60, 138-144 (1996).
7. L. Bertilsson: Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29, 192-209 (1995).
8. D. A. Flockhart: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin. Pharmacokinet. 29 (Suppl. 1), 45-52 (1995).
9. T. Andersson, K. Andrén, C. Cederberg, G. Edvardsson, A. Heggelund, and P. Lundborg: Effect of omeprazole and cimetidine on plasma diazepam levels. Eur. J. Clin. Pharmacol. 39, 51-54 (1990).
10. T. Andersson, C. Cederberg, G. Edvardsson, A. Heggelund, and P. Lundborg: Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47, 79-85 (1990).
11. R. Gugler and J. C. Jensen: Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89, 1235-1241 (1985).
12. P. J. Prichard, R. P. Walt, G. K. Kitchingman, K. W. Somerville, and M. J. S. Langman: Oral phenytoin pharmacokinetics during omeprazole therapy. Br. J. Clin. Pharmacol. 24, 543-545 (1987).
13. D. A. Henry, K. W. Somerville, G. Kitchingman, and M. J. S. Langman: Omeprazole. Effects on oxidative drug metabolism. Br. J. Clin. Pharmacol. 18, 195-200 (1984).
14. L. E. Gustavson, J. F. Kaiser, A. L. Edmonds, C. S. Locke, M. L. Debartolo, and D. W. Schneck: Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. 39, 2078-2083 (1995).
15. R. Curi-Pedrosa, M. Daujat, L. Pichard, J. C. Ourlin, P. Clair, L. Gervot, P. Lesca, J. Domergue, H. Joyeux, G. Fourtanier, and P. Maurel: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 269, 384-392 (1994).
16. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 52, 170-180 (1992).
17. T. Andersson, P. Lundborg, and C. G. Regårdh: Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur. J. Clin. Pharmacol. 40, 61-65 (1991).
18. D. Henry, P. Brent, I. Whyte, G. Mihaly, and S. Devenish-Meares: Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur. J. Clin. Pharmacol. 33, 369-373 (1987).
19. P. Unge, L.-E. Svedberg, A. Nordgren, H. Blom, T. Andersson, P.-O. Lagerström, and J.-P. Idström: A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br. J. Clin. Pharmacol. 34, 509-512 (1992).
20. T. Andersson, J. O. Miners, M. E. Veronese, W. Tassaneeyakul, W. Tassaneeyakul, U. A. Meyer, and D. J. Birkett: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36, 521-530 (1993).
21. T. Andersson, C.-G. Regårdh, Y.-C. Lou, Y. Zhang, M.-L. Dahl, and L. Bertilsson: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2, 25-31 (1992).
22. D.-R. Sohn, K. Kobayashi, K. Chiba, K.-H. Lee, S.-G. Shin, and T. Ishizaki: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J. Pharmacol. Exp. Ther. 262, 1195-1202 (1992).
23. D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. De La Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
24. S. J. Baldwin, J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261-270 (1995).
25. F. Broly, C. Libersa, M. Lhermitte, P. Bechtel, and B. Dupuis: Effect of i quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br. J. Clin. Pharmacol. 28, 29-36 (1989).
26. F. P. Guengerich, D. H. Kim, and M. Iwasaki: Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
27. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
28. M. Tateno and N. Nakamura: Phase I study of lansoprazole (AG-1749) antiulcer agent. Capsule form. Rinsho Iyaku 7, 51-62 (1991).
29. L. Pichard, R. Curi-Pedrosa, C. Bonfils, E. Jacqz-Aigrain, J. Domergue, H. Joyeux, J. Cosme, F. P. Guengerich, and P. Maurel: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol. Pharmacol. 47, 410-418 (1995).
30. R. E. Pearce, D. Rodrigues, J. A. Goldstein, and A. Parkinson: Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277, 805-816 (1996).
31. R. A. Lefebvre, B. Flouvat, S. Karolac-Tamisier, E. Moerman, and E. V. Ganse: Influence of lansoprazole treatment on diazepam plasma concentrations. Clin. Pharmacol. Ther. 52, 458-463 (1992).
32. M. D. Karol, D. Mukherji, and J. H. Cavanaugh: Lack of effect of concomitant multidose lansoprazole on single-dose phenytoin pharmacokinetics in subjects. Gastroenterology 106 (Suppl.), A103 (abstr.) (1994).
33. J. A. Salcedo, S. U. Yasuda, M. P. Murphy, R. L. Woosley, and D. A. Flockhart: Stereoselective inhibition of CYP2D6 by chlorpheniramine. Clin. Pharmacol. Ther. 57, 149 (abstr.) (1995).
34. R. C. Halliday, B. C. Jones, D. A. Smith, N. R. Kitteringham, and B. K. Park: An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br. J. Clin. Pharmacol. 40, 369-378 (1995).
35. S. V. Otton, H. K. Crewe, M. S. Lennard, G. T. Tucker, and H. F. Woods: Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol Exp. Ther. 247, 242-247 (1988).
36. D. Wu, S. V. Otton, B. A. Sproule, U. Busto, T. Inaba, W. Kalow, and E. M. Sellers: Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br. J. Clin. Pharmacol. 35, 30-34 (1993).
37. S. V. Otton, D. Wu, R. T. Joffe, S. W. Cheung, and E. M. Sellers: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53, 401-409 (1993).
38. J. W. Harris, A. Rahman, B.-R. Kim, F. P. Guengerich, and J. M. Collins: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
39. H. B. Pollard, R. Menard, H. A. Brandt, C. J. Pazolzs, C. E. Creutz, and A. Ramu: Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal. Biochem. 86, 761-763 (1978).
40. W. Tassaneeyakul, D. J. Birkett, M. E. Veronese, M. E. McManus, R. H. Tukey, L. C. Quattrochi, H. V. Gelboin, and J. O. Miners: Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407 (1993).
41. M. V. Relling, T. Aoyama, F. J. Gonzalez, and U. A. Meyer: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447 (1990).
42. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. VandenBranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
43. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
44. 14C]dextromethorphan. Anal. Biochem. 219, 309-320 (1994).
45. J. C. Gorski, D. R. Jones, S. A. Wrighton, and S. D. Hall: Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 48, 173-182 (1994).
46. R. B. Kim, H. Yamazaki, K. Chiba, D. O'Shea, M. Mimura, F. P. Guengerich, T. Ishizaki, T. Shimada, and G. R. Wilkinson: In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J. Pharmacol. Exp. Ther. 279, 4-11 (1996).
47. M. VandenBranden, B. J. Ring, S. N. Binkley, and S. A. Wrighton: Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6, 81-91 (1996).
48. K. Chiba, K. Kobayashi, K. Manabe, M. Tani, T. Kamataki, and T. Ishizaki: Oxidative metabolism of omeprazole in human liver microsomes: cosegreation with S-mephenytoin 4′-hydroxylation. J. Pharmacoi. Exp. Ther. 266, 52-59 (1993).
49. T. Andersson, J. O. Miners, M. E. Veronese, and D. J. Birkett: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 37, 594-604 (1994).
50. L. Bertilsson, T. K. Henthorn, E. Sanz, G. Tybring, J. Säwe, and T. Villén: Importance of genetic factors in the regulation of diazepam metabolism. Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45, 348-355 (1989).
51. T. Andersson: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole, and pantoprazole. Clin. Pharmacokinet. 31, 9-28 (1996).
52. G. Li and U. Klotz: Inhibitory effect of omeprazole on the metabolism of midazolam in vitro. Arzneim-Forsch/Drug Res. 40, 1105-1107 (1990).
53. J. A. Salcedo, J. H. Lewis, N. Sukhova, S. B. Benjamin, and D. A. Flockhart: Clarithromycin inhibits omeprazole metabolism in human liver microsomes. Gastroenterology 110, A248 (abstr.) (1996).
54. M. D. Karol, M. Mayersohn, C. J. Eason, H. Shi, and J. Cavanaugh: Evaluation of interaction potential between lansoprazole and clarithromycin in normal subjects. Am. J. Gastroenterol. 90 (Suppl.), 192 (abstr.) (1995).
55. I. Blohmé, J.-P. Idström, and T. Andersson: A study of the interaction between omeprazole and cyclosporin in renal transplant patients. Br. J. Clin. Pharmacol. 35, 156-160 (1993).
56. L. Schouler, F. Dumas, P. Couzigou, G. Janvier, S. Winnock, and J. Saric: Omeprazole-cyclosporin interaction. Am. J. Gastroenterol. 86, 1097 (letter) (1991).
57. R. Arranz, E. Yañez, J. L. Franceschi, and J. M. Fernandez-Rañada: More about omeprazole-cyclosporin interaction. Am. J. Gastroenterol. 88, 1093-1094 (letter) (1993).
58. K. L. Kunze, L. C. Wienkers, K. E. Thummel, and W. F. Trager: Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
59. M. E. Veronese, P. I. Mackenzie, C. J. Doecke, M. E. McManus, J. O. Miners, and D. J. Birkett: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochem. Biophys. Res. Commun. 175, 1112-1118 (1991).
60. J. H. Cavanaugh, E. P. Winters, A. Cohen, C. S. Locke, and R. Braeckman: Lack of effect of lansoprazole on steady state warfarin metabolism. Gastroenterology 100 (Suppl.), A40 (abstr.) (1991).
61. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem. Pharmacol. 42, 347-355 (1991).
62. J. R. Halpert, F. P. Guengerich, J. R. Bend, and M. A. Correia: Contemporary issues in toxicology: selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 125, 163-175 (1994).
63. J. O. Miners, M. E. Veronese, and D. J. Birkett: In vitro approaches for the prediction of human drug metabolism. Ann. Rept. Med. Chem. 29, 307-316 (1994).
64. M. Bourriè, V. Meunier, Y. Berger, and G. Fabre: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277, 321-332 (1996).
65. A. D. Rodrigues: Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem. Pharmacol. 48, 2147-2156 (1994).